|
Group
|
Dilution or treatment
|
Mean incubation time in days ± SD (% survival)
|
|---|
| |
RML titration series
*
| |
| |
100
|
66 ± 3.4 (0%)
|
| |
10-1
|
74 ± 3.3 (0%)
|
| |
10-2
|
83 ± 6.1 (0%)
|
| |
10-3
|
128 ± 29.1 (22%)
|
| |
10-4
|
184 ± 39.6 (78%)
|
| |
10-5 through 10-12
|
N/A (100%) – study termination
|
| |
Treated RML
| |
| |
SPC-PL*
|
67 ± 2.6 (0%)
|
| |
SPC-PH*
|
70 ± 6.0 (0%)
|
| |
SPC-PL + SDS*
|
93 ± 9.7 (0%)
|
| |
SPC-PH + SDS*
|
93 ± 7.6 (0%)
|
|
1
|
SPC-PL ∏ PK
|
107 ± 39.0 (11%)
|
|
2
|
SPC-PH ∏ PK
|
98 ± 16.8 (0%)
|
|
3
|
SPC-PL + SDS ∏ PK
|
431 ± 72.4 (73%)
|
|
4
|
SPC-PH + SDS ∏ PK
|
108^ (88%)
|
|
5
|
SDS control
|
85 ± 12.3 (0%)
|
|
6
|
PK control
|
62 ± 5.2 (0%)
|
|
7
|
SDS ∏ PK control
|
86 ± 7.1 (0%)
|
- *Smith et al.[29]; ^only 1 mouse in this group was euthanized due to clinical scrapie.
- SD standard deviation.
